FDA Clears Schering Antipsychotic Drug | August 24, 2009 Issue - Vol. 87 Issue 34 | Chemical & Engineering News
Volume 87 Issue 34 | p. 20 | Concentrates
Issue Date: August 24, 2009

FDA Clears Schering Antipsychotic Drug

Department: Business
Keywords: Dow Chemical, Getty Conservation Institute, Tate

FDA has approved Schering-Plough's antipsychotic drug, Saphris, for acute treatment of schizophrenia in adults and for episodes associated with severe bipolar-1 disorder. The drug will compete with Johnson & Johnson's Risperdal, Bristol-Myers Squibb's Abilify, and Eli Lilly & Co.'s Zyprexa. Schering, which is being acquired by Merck & Co., projects sales of Saphris to exceed $1 billion per year. Schering acquired the drug when it purchased Organon BioSciences in 2007.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment